Eurobio Scientific: Robust First Half of 2024 Amid Uncertainty

In the first half of 2024, Eurobio Scientific reported a 24% increase in revenues, reaching €73.4 million compared to €59.1 million in the same period of 2023. Excluding acquisition effects, the growth stands at 12%. Key contributors were GenDx and the French market, with increases of 32% and 8%, respectively. Despite an uncertain environment, the company maintained its strategic focus.

The share of proprietary products remained stable at 29%, while international revenues grew to 42% of the total, largely due to new acquisitions and cross-sales of proprietary products. These moves align with Eurobio's strategy to become a leading player in specialty diagnostics.

A consortium including IK Partners and Nextstage AM has agreed with Eurobio Scientific to launch a voluntary tender offer. This initiative highlights the continued confidence in Eurobio's strategic direction and growth potential.